Atazanavir plus low-dose ritonavir in pregnancy: Pharmacokinetics and placental transfer

AIDS

Volumn 21, Issue 18, 2007, Pages 2409-2415

  Ripamonti, Diego ^a   Cattaneo, Dario ^b   Maggiolo, Franco ^a   Airoldi, Monica ^a   Frigerio, Luigi ^a   Bertuletti, Pierangelo ^a   Ruggeri, Maurizio ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Atazanavir; HIV 1 infection; Pharmacokinetics; Placental transfer; Pregnancy

Indexed keywords

ATAZANAVIR; LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOW DRUG DOSE; PLACENTAL TRANSFER; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEADY STATE; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; WILD TYPE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE TRANSMISSION, VERTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; OLIGOPEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PYRIDINES; RITONAVIR;

EID: 36348967131     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32825a69d1     Document Type: Article

References (26)

1. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300.
2. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829.
3. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43:1071-1087.
4. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and non pregnant women. Br J Pharmacol 2006; 62:309-315.
5. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
6. Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatography coupled assay for the protease inhibitor atazanavir in plasma. Biomed Chromatogr 2006; 20:72-76.
7. Colombo S, Beguin A, Marzolini C, Telenti A, Biollaz J, Decosterd LA. Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 832:138-143; E-pub 15 December 2005.
8. Center for Drug Evaluation and Research, Draft guidance for industry: pharmacokinetics in pregnancy - study design, data analysis, and impact on dosing and labeling, Washington, DC, US Department of Health and Humans Services, Food and Drug Administration. October 2004. Available at: http://www.fda.gov/cder/guidance/5917dft.htm Accessed: January 2007.
9. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, et al. In vitro profile of the human immunodeficiency type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-2326.
10. Barrios A, Rendon AL, Gallego O, Martin-Carbonero L, Valer L, Rios P, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004; 5:201-205.
11. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430-436.
12. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17:1195-1199.
13. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extremely pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359.
14. Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49:1720-1726.
15. Natha M, Hay P, Taylor G, Wood C, Sarner L, Cunningham L, et al. Atazanavir use in pregnancy: a report of 33 cases, In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 25-28 February 2007. Poster 750.
16. Bertz R, Wang Y, Mahnke L, Persson A, Chung E, Mathew M, et al. Assessment of pharmacokinetic/pharmacodynamic relationships through 48 weeks from a study in HIV+, ART-naive subjects receiving antiretroviral regimens containing atazanavir 400 mg or atazanavir/ritonavir 300/100 mg once daily. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 25-28 February 2007. Poster 565.
17. Taburet AM, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
18. Colombo S, Buclin T, Cavassini M, Decosterd LA, Telenti A, Biollaz J, Csajka C. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:3801-3808.
19. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez-Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21: 41-46.
20. Cassard B, Rouault A, Damond F, Pattyn A, Batallan A, Longuet P, et al. Therapeutic drug monitoring of lopinavir/ritonavir (LPV/RTV) containing regimen in pregnant HIV-infected women. In: 3rd IAS Conference. Rio de Janeiro, Brazil. 24-27 July 2005. Abstract WePe3.2C09.
21. Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743.
22. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16:889-893.
23. Regazzi MB, Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, et al. Effects of pregnancy on protease inhibitors (PIs) pharmacokinetics in HIV-1 infected women. In: 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, 20-22 April 2006. Poster 27.
24. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004; 191:558-562.
25. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: a case report. AIDS 2006; 20:307.
26. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr 2002; 29 (Suppl. 1):S11-S18.